MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 289 filers reported holding MYRIAD GENETICS INC in Q3 2018. The put-call ratio across all filers is 1.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $308,000 | +5.1% | 9,542 | -0.5% | 0.00% | – |
| Q2 2021 | $293,000 | +12.7% | 9,594 | -47.2% | 0.00% | – |
| Q1 2020 | $260,000 | -36.7% | 18,155 | +20.2% | 0.00% | -100.0% |
| Q4 2019 | $411,000 | +30.5% | 15,106 | +59.1% | 0.00% | – |
| Q1 2019 | $315,000 | +43.2% | 9,493 | +25.4% | 0.00% | – |
| Q4 2018 | $220,000 | -30.8% | 7,570 | +9.4% | 0.00% | – |
| Q3 2018 | $318,000 | +46.5% | 6,919 | +9.3% | 0.00% | – |
| Q4 2017 | $217,000 | -34.0% | 6,331 | -30.4% | 0.00% | -100.0% |
| Q3 2017 | $329,000 | -4.9% | 9,097 | -10.6% | 0.00% | -50.0% |
| Q4 2014 | $346,000 | -11.3% | 10,173 | +0.7% | 0.00% | 0.0% |
| Q3 2014 | $390,000 | -66.1% | 10,107 | -65.8% | 0.00% | -71.4% |
| Q2 2014 | $1,149,000 | +143.4% | 29,532 | +68.3% | 0.01% | +75.0% |
| Q2 2013 | $472,000 | – | 17,552 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,750,000 | $75,900,000 | 2.61% |
| PFM Health Sciences, LP | 2,025,681 | $55,909,000 | 1.90% |
| Tieton Capital Management, LLC | 118,456 | $3,269,000 | 1.83% |
| Altium Capital Management LP | 190,000 | $5,244,000 | 1.45% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,846,490 | $50,963,000 | 1.03% |
| EARNEST PARTNERS LLC | 6,316,365 | $174,332,000 | 1.01% |
| Glenview Capital Management | 1,679,747 | $46,361,000 | 0.99% |
| Zebra Capital Management LLC | 14,209 | $392,000 | 0.63% |
| AIMZ Investment Advisors, LLC | 44,185 | $1,220,000 | 0.48% |
| Phocas Financial Corp. | 132,101 | $3,646,000 | 0.46% |